#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | #LCSM Chat @lcsmchat @BrendonStilesMD @LungCancerFaces Stop teasing, Stiles. |
 | Brendon Stiles @BrendonStilesMD Excited for everyone to be here. Yes it was #WCLC20 , but it was a great way to start 2021! #lcsm |
 | Henning Willers, MD, FASTRO @HenningWillers @HenningWillers #radonc #physicianscientist @MGHCancerCenter here, Trying to participate while fighting off kids (I might not win this one though ;-) ...) #lcsm |
 | Sara Whitlock @sjwhitlock @BrendonStilesMD Wouldn’t that be grand. Miss you! And oh so proud of you and your new gig!!!! |
 | Lung Cancer Sux @LungCancerSux Glorianne from CT. Caregiver. Hubby is >10 years stage IV #LCSM |
| Brendon Stiles @BrendonStilesMD #wclc20 was yet another great meeting from @iaslc. Certainly the best multidisciplinary meeting I am a part of. #lcsm |
 | Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD Hi everyone, joining in from Philly! Med Onc at @PennCancer. Good to see everyone! #LCSM |
| Brendon Stiles @BrendonStilesMD I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm |
| Brendon Stiles @BrendonStilesMD That said….it has been a great year for lung cancer. This was obvious at #wclc20 #lcsm |
 | Stephen V Liu, MD @StephenVLiu RT @LungCancerFaces: ATTENTION #LCSM! Less than 30 minutes until #LCSM Chat. Please join moderator @BrendonStilesMD as he presents “#WCLC20… |
| Brendon Stiles @BrendonStilesMD @CharuAggarwalMD @PennCancer Hi Charu! #lcsm |
 | K.B. @kbutler127 RT @lgreco_ny: Please share like your life depends on it. LIVES DO DEPEND ON IT. Churchill: Why won't New York vaccinate the vulnerable? #l… |
| @LungCancerFaces Deana in Los Angeles here. I’ll be tweeting from the @lcsmchat account tonight. Join us now. https://t.co/WrClVC9owF #lcsm | |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD Tremendous year! #LCSM |
| Brendon Stiles @BrendonStilesMD For tonight’s chat: more info at https://t.co/Lx9qF406C9 #lcsm |
 | caius kim @caiuskim Caius here. #LCSM |
 | Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD Amen. Ready for some in-person cameraderie! #LCSM |
| Brendon Stiles @BrendonStilesMD You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD 😭😭😭 |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: @BrendonStilesMD Amen. Ready for some in-person cameraderie! #LCSM |
| #LCSM Chat @lcsmchat [REDACTED USER] Hey Margot! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Janet here from overcast Seattle. Glad to "see" my #LCSM tweeps again! |
| Brendon Stiles @BrendonStilesMD To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. #lcsm |
| #LCSM Chat @lcsmchat @LungCancerSux Hey Glorianne! #lcsm |
 | Jill Feldman @jillfeldman4 #WCLC20 is great because I could follow tweets/threads from @Jbauml @StephenVLiu @CharuAggarwalMD & others BUT I miss seeing everyone IRL #LCSM |
 | Matthew Smeltzer @MattSmeltzer @BrendonStilesMD Agree, but #WCLC20 was the best virtual meeting so far! |
 | Lisa Cunningham @LisaGemini Me too! And I want the CCP punished! |
| Brendon Stiles @BrendonStilesMD We'll get started in a few minutes -- please take a moment to introduce yourselves. #lcsm |
| Henning Willers, MD, FASTRO @HenningWillers @BrendonStilesMD https://t.co/yIbKJBgfWO is also a good one #lcsm |
| #LCSM Chat @lcsmchat @HenningWillers @MGHCancerCenter We’ll hope for the best. #lcsm |
 | Sue McCullough @SueMcCu30398663 @JFreemanDaily I am here to but it's my first time on twitter chatter! |
 | Eric Bernicker MD FASCO @EricBernicker Happy to be here. Eric, a thoracic medical oncologist from Houston. #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @jillfeldman4 @Jbauml @StephenVLiu Miss seeing you Jill, your talk was incredible! 🤗 #LCSM |
| Brendon Stiles @BrendonStilesMD @HenningWillers Indeed. tchat giving me trouble tonight! #lcsm |
| Janet Freeman-Daily @JFreemanDaily [REDACTED USER] @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can read tonight's topic questions here: https://t.co/g6Dul2e8Mw |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: For tonight’s chat: more info at https://t.co/Lx9qF406C9 #lcsm |
| Jill Feldman @jillfeldman4 @CharuAggarwalMD @Jbauml @StephenVLiu Thank you! |
| Sara Whitlock @sjwhitlock @jillfeldman4 @Jbauml @StephenVLiu @CharuAggarwalMD Your descriptions of the presentations and posters were GOLD!! |
| Brendon Stiles @BrendonStilesMD I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Also still a bit pissed that my dad died from lung cancer. #LCSM https://t.co/nHFeKsKOXN |
| #LCSM Chat @lcsmchat @caiuskim Welcome! Thanks for joining us. #lcsm |
 | Deb 🌅 @debsmithbeach Deb from NH here. In Boston tonight, scans early tomorrow. #LCSM |
| Brendon Stiles @BrendonStilesMD @MattSmeltzer Hi Matt! #lcsm |
| @KimballKristen Kris here from Boston, hello! #LCSM | |
| Brendon Stiles @BrendonStilesMD I would like to disclose conflicts – I am the Board Chair of @lcrf_org & have worked with @astrazeneca @pfizer @bmsnews @genentech & others. These don’t affect opinions expressed tonight. #lcsm |
| #LCSM Chat @lcsmchat [REDACTED USER] @BrendonStilesMD We can certainly discuss this after tonight’s chat. I lost my mom to lung cancer, too. xo #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| Brendon Stiles @BrendonStilesMD In this week’s chat we hope to review some lung cancer highlights from #WCLC20 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twi… |
 | Dave Bjork @bjork5 @BrendonStilesMD Hey @BrendonStilesMD sorry I’m late! Dave here joining from Boston 🙌 #LCSM |
| Matthew Smeltzer @MattSmeltzer Hi everyone! Matt from Memphis #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves. #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD https://t.co/yIbKJBgfWO is also a good one #lcsm |
| #LCSM Chat @lcsmchat @EricBernicker Yay! Welcome. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @SueMcCu30398663 Good to see you Sue! #LCSM |
 | Laura Greco @lgreco_ny Hello! Laura here. Greetings from upstate NY #lcsm |
 | Student Network Organization @SNO_TUFH February 4 is marked as World Cancer Day which is celebrated to encourage its prevention, detection, and treatment! #letsfightittogether #iamandiwill #worldcancerday2021 SNO EMRO: https://t.co/i8uUmyMfN8 SNO SE Asia: https://t.co/85xlCEsOpq SNO Africa: https://t.co/rKi2ZBjkkn |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: [REDACTED USER] @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can r… |
| Brendon Stiles @BrendonStilesMD @bjork5 Dave....my man. Thanks for joining! #LCSM If you haven't heard his podcasts, you are missing out! |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Also still a bit pissed that… |
| Brendon Stiles @BrendonStilesMD [REDACTED USER] Hi Lillian! #lcsm |
| Dave Bjork @bjork5 @CharuAggarwalMD @BrendonStilesMD Hey Charu! #lcsm |
| #LCSM Chat @lcsmchat @debsmithbeach Best hopes, Deb. #lcsm |
| #LCSM Chat @lcsmchat @KimballKristen Hey lady! #lcsm |
 | Anything's Natural Skincare @AnythngsNatural @major___moves @alwaysSFTC We are an all natural, organic and cruelty free black owned skincare business. Our whipped body butters are crafted for those with all skin types and caters to skin types that are dry, sensitive, Eczema and Psoriasis prone. https://t.co/ECOpUHpGuC https://t.co/i49OIk3p3T |
| Dave Bjork @bjork5 RT @jillfeldman4: #WCLC20 is great because I could follow tweets/threads from @Jbauml @StephenVLiu @CharuAggarwalMD & others BUT I miss see… |
| Brendon Stiles @BrendonStilesMD #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross Soo #lcsm: https://t.co/xqRNI2ZpZT |
 | Peggy Dennis @peggyddennis #lcsm. Peggy joining a bit late from Denver |
| #LCSM Chat @lcsmchat [REDACTED USER] Woo HOO! Hello! #lcsm |
| Brendon Stiles @BrendonStilesMD Here are t@APassaroMD top 5 presentations https://t.co/6iLv2xb3Bc #lcsm |
 | Nathan A. Pennell MD, PhD, FASCO @n8pennell @BrendonStilesMD Gotcha brother. Lung cancer can kiss my a$$. https://t.co/h4ysoaPKkG |
| Dave Bjork @bjork5 @debsmithbeach Good luck 🙏🏽 #lcsm |
| Jill Feldman @jillfeldman4 RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S… |
| #LCSM Chat @lcsmchat @MattSmeltzer Welcome! #lcsm |
| Matthew Smeltzer @MattSmeltzer @BrendonStilesMD Hi @BrendonStilesMD ! Like @HenningWillers I am juggling commitments! |
| Brendon Stiles @BrendonStilesMD We will get started soon. First, a few reminders… #lcsm |
| @aepriceny @lcsmchat ann price here survivor, just retired this week, so I can enjoy my life--here to listen #lcsm | |
| Brendon Stiles @BrendonStilesMD Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
| Dave Bjork @bjork5 @KimballKristen Boston is representing tonight! #LCSM |
| Janet Freeman-Daily @JFreemanDaily Why do I get the feeling I'm not seeing all the tweets in #LCSM Chat? I see replies, but can't always see the original messages. **sigh** |
| Henning Willers, MD, FASTRO @HenningWillers @BrendonStilesMD hmmpf, as usual no #radonc advances (we need to do better) #lcsm |
| Brendon Stiles @BrendonStilesMD If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
| #LCSM Chat @lcsmchat @SueMcCu30398663 @JFreemanDaily Hi Sue! Remember to include #lcsm in your tweets and you’ll be just fine. |
| Brendon Stiles @BrendonStilesMD I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Nate Pennell, oncologist in Cleveland! Hi all. #lcsm |
| @CroixDenise Hello! #LCSM | |
| #LCSM Chat @lcsmchat @lgreco_ny Hey spitfire! #lcsm |
 | mimiprovenzano @MimiProvenzano Hi everybody, sorry I'm late! #LCSM |
| Brendon Stiles @BrendonStilesMD We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
| Jill Feldman @jillfeldman4 @JFreemanDaily Me too! And they seem to come in late? |
| #LCSM Chat @lcsmchat @peggyddennis Hi Peggy #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Here are t@APassaroMD top 5 presentations https://t.co/6iLv2xb3Bc #lcsm |
| Brendon Stiles @BrendonStilesMD @HenningWillers Too many to describe! #lcsm |
| #LCSM Chat @lcsmchat @aepriceny Hi Ann! #lcsm |
| @KimballKristen @lcsmchat Hey there, Deana! #LCSM | |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers @BrendonStilesMD We can't cover everything in one hour! I believe some #radonc advances were presented in the #STS conference on the same weekend as #WCLC20. #LCSM |
 | Deepti Behl, M.D. @deeptibehl1 @lcsmchat @EricBernicker Hello everyone @lcsmchat Deepti Behl from Sacramento |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD hmmpf, as usual no #radonc advances (we need to do better) #lcsm |
| Dave Bjork @bjork5 @BrendonStilesMD You rock this Brendon! #LCSM |
| Brendon Stiles @BrendonStilesMD T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol… |
| Brendon Stiles @BrendonStilesMD T1. This has long been a data free zone. #lcsm |
 | Ashlie Nicole @ashlie_nicole18 #livelaughlove #furbabies #positivity #relaxation #catsofinstagram #smile #rheumatoidarthritis #lupus #sjogrens #fibromyalgia #hidradenitissuppurativa #survivor https://t.co/SXelBRPWRf |
| Brendon Stiles @BrendonStilesMD T1. Although I understand the desire for this in the #lcsm community, challenge to justify expected costs, low + rates, and potential complications. #lcsm |
| Dave Bjork @bjork5 Woohoo! @NarjustDumaMD 🙌 #LCSM |
| #LCSM Chat @lcsmchat @n8pennell Hello famous @people correspondent. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. In general, I have always argued that we need to show that we can be successful in approved populations before expanding more broadly. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat @CroixDenise Welcome! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. This has long been a data free zone. #lcsm |
| #LCSM Chat @lcsmchat @MimiProvenzano Hi Mimi #lcsm |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
| Stephen V Liu, MD @StephenVLiu RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| Brendon Stiles @BrendonStilesMD T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers @BrendonStilesMD We can't cover everything in one hour! I believe some #radonc advances were presented… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. In general, I have always argued that we need to show that we can be successful in approved populations before ex… |
| #LCSM Chat @lcsmchat [REDACTED USER] Hi Kim #lcsm |
| mimiprovenzano @MimiProvenzano @lcsmchat Hey Deanna! #lcsm |
| Jill Feldman @jillfeldman4 T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of the time it's not cancer. Not easy to tell someone (who knows nothing about #lungcancer) that a small nodule was found but wait 6 mths to scan #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Although I understand the desire for this in the #lcsm community, challenge to justify expected costs, low + rate… |
| Brendon Stiles @BrendonStilesMD T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. In general, I have always argued that we need to show that we can be successful in approved populations before ex… |
| @KimballKristen @JFreemanDaily It does seem more difficult tonight! #LCSM | |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI |
 | Inspire @InspireIsHealth Hello to the #lcsm community, John Novack grateful here on behalf of Inspire, to listen and learn. |
| Brendon Stiles @BrendonStilesMD T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm https://t.co/xVcsLLWGHn |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI |
 | Kimberley H Geissler @khgeissler @BrendonStilesMD T1. Is there any evidence of higher risk in eg, never smoker daughter of never smoker with LC? #lcsm |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T1: there’s definitely a need. You’re referring to the TALENT trial that used CT screening in non-smokers in Taiwan. But it will be hard to show a similar impact in a region with a lower incidence. Balance benefit with cost and risks. #LCSM |
| Brendon Stiles @BrendonStilesMD T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0 |
| Deepti Behl, M.D. @deeptibehl1 @JFreemanDaily Yes me too, feel like not seeing it all #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T1. The Taiwan screening study (2.6% I think incidence in nonsmokers) suggests at least there screening makes great sense. Unclear how much that translates outside Asia. #lcsm |
 | Jamie Holloway, PhD @jamienholloway Jumping in late to the #LCSM chat, eager to hear more from world lung! |
| Jill Feldman @jillfeldman4 T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, radon, etc. It's ridiculous that current guidelines only include smoking history and age - it's an incomplete way & misses a lot of people #LCSM |
| Brendon Stiles @BrendonStilesMD T1. The most important slide to me was the one that showed association with family history. Clearly should consider that as a criteria for screening. #lcsm https://t.co/cOkcpwmeUU |
| #LCSM Chat @lcsmchat @deeptibehl1 @EricBernicker Welcome! Remember to include #lcsm in your tweets so we can see them during the chat. |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm h… |
| Sue McCullough @SueMcCu30398663 #LCSM I think I will just watch the tweets for a while, I much rather talking, I just don't type fast. |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0 |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm h… |
| #LCSM Chat @lcsmchat @teaminspire Hi John #lcsm |
| Brendon Stiles @BrendonStilesMD T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.co/x9hPPhI5pa Is there likely an inheritable risk of lung cancer... #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm h… |
| #LCSM Chat @lcsmchat RT @khgeissler: @BrendonStilesMD T1. Is there any evidence of higher risk in eg, never smoker daughter of never smoker with LC? #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: T1. The Taiwan screening study (2.6% I think incidence in nonsmokers) suggests at least there screening makes great sense. U… |
| Janet Freeman-Daily @JFreemanDaily [REDACTED USER] @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will benefit enough from #lungcancer screening to justify the risks. Can only due that through a clinical trial. #LCSM |
| #LCSM Chat @lcsmchat @jamienholloway Thanks for joining! #lcsm |
| Brendon Stiles @BrendonStilesMD [REDACTED USER] @JFreemanDaily I am going to hug the heck out of many people. It is going to be uncomfortable. Apologizing in advance. #lcsm |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more prevalent than we previously thought. #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, rad… |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider… |
 | KRASKickers @KRASKickers @JFreemanDaily #LCSM chat Hey all - I am fashionably late this evening ./ This is Terri |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm h… |
| #LCSM Chat @lcsmchat @SueMcCu30398663 We were all newbies once. You’ll get the hang of it. I promise. #lcsm |
| @aepriceny @BrendonStilesMD @lcsmchat Vaccine #1 down! I’m d so done with zoom. | |
| Brendon Stiles @BrendonStilesMD @StephenVLiu Totally agree. But it starts us on a dialogue for identifying risk - genetic, ethnic, environmental. We'll get there eventually. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.c… |
| Jill Feldman @jillfeldman4 [REDACTED USER] Educating people is key. I feel like once it's explained in a way that people can understand it's less anxiety provoking, but there are still those who won't be able to compartmentalize and there is no easy way to do a lung biopsy! #LCSM |
| Eric Bernicker MD FASCO @EricBernicker @jillfeldman4 Completely agree but until we prove that we can screen folks with a certain smoking history--and the numbers are awful--expanding to other populations will be difficult #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: [REDACTED USER] @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will be… |
| Stephen V Liu, MD @StephenVLiu RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S… |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, rad… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider… |
| #LCSM Chat @lcsmchat @kRasKickers @JFreemanDaily Hey Terri! #lcdm |
 | qualitycpr4all @timika_edney Now open: #corporate #community #training with #COVID19 #safety #precautions using #hocmanlearningsystem #new #supportlocalbusiness #mobilecprjawn #heartmonth #vaccinated https://t.co/p56rsHmlLi |
| Brendon Stiles @BrendonStilesMD Another of my all time favorites! Love seeing your here! #lcsm |
| #LCSM Chat @lcsmchat @kRasKickers @JFreemanDaily Hey Terri! #lcsm |
| Jill Feldman @jillfeldman4 RT @StephenVLiu: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more pre… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @StephenVLiu Totally agree. But it starts us on a dialogue for identifying risk - genetic, ethnic, environmental. We… |
| #LCSM Chat @lcsmchat RT @jillfeldman4: [REDACTED USER] Educating people is key. I feel like once it's explained in a way that people can understand it's less anx… |
| Jill Feldman @jillfeldman4 RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.c… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.c… |
| KRASKickers @KRASKickers @lcsmchat @JFreemanDaily 😎 |
| Eric Bernicker MD FASCO @EricBernicker @BrendonStilesMD @StephenVLiu I am hopeful that the increasing recognition on the need for environmental justice and pollution will lead to this being explored more thoroughly #LCSM |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screening strategies in the not too distant future. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @JFreemanDaily: [REDACTED USER] @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will be… |
| Jill Feldman @jillfeldman4 @EricBernicker Yes, but it's moving at a snails pace 😫 |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more pre… |
| Inspire @InspireIsHealth RT @JFreemanDaily: [REDACTED USER] @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will be… |
| Brendon Stiles @BrendonStilesMD T2 coming soon. Long way to go on screening never smokers, but research and trials will get us there. In the interim, let's increase screening rates in eligible patients! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: [REDACTED USER] Educating people is key. I feel like once it's explained in a way that people can understand it's less anx… |
| #LCSM Chat @lcsmchat I see you @SeastedtMD! Thanks for joining us. #lcsm |
| @KimballKristen T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died of EGFR+ LC. Hoping for biomarker or other breakthroughs for them & all ppl #lcsm | |
| Jill Feldman @jillfeldman4 [REDACTED USER] The Holy Grail of early detection! #LCSM |
| Matthew Smeltzer @MattSmeltzer @BrendonStilesMD T1: any guesses how much this will vary by population? |
| Laura Greco @lgreco_ny @StephenVLiu @BrendonStilesMD T1: I think this will be a game changer. #LCSM |
| Inspire @InspireIsHealth RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider… |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Definitely something to look forward to in the future #LCSM |
| Brendon Stiles @BrendonStilesMD T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm |
| #LCSM Chat @lcsmchat RT @EricBernicker: @BrendonStilesMD @StephenVLiu I am hopeful that the increasing recognition on the need for environmental justice and pol… |
| Brendon Stiles @BrendonStilesMD @MattSmeltzer Dramatically is my guess! #lcsm |
| #LCSM Chat @lcsmchat RT @KimballKristen: T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died o… |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screenin… |
| @KimballKristen @StephenVLiu @BrendonStilesMD Yes, hopping for this! #LCSM | |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2 coming soon. Long way to go on screening never smokers, but research and trials will get us there. In the interim… |
| Janet Freeman-Daily @JFreemanDaily RT @KimballKristen: T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died o… |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Definitely something to look forward to in the future #LCSM https://t.co/yaWjiktlZs |
| #LCSM Chat @lcsmchat #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #Test #LCSM |
| Brendon Stiles @BrendonStilesMD T2. Tough target, long time coming. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #T… |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatment. Use in the first line will need to be combinations unless we can further in which the population that get long-term benefit. #LCSM |
| Jill Feldman @jillfeldman4 [REDACTED USER] We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not too much to ask for :) #LCSM |
| KRASKickers @KRASKickers RT @JFreemanDaily: [REDACTED USER] @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can r… |
| @lori_burwell RT @lgreco_ny: Please share like your life depends on it. LIVES DO DEPEND ON IT. Churchill: Why won't New York vaccinate the vulnerable? #l… | |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Reinforces the need for comprehensive molecular testing #NGS #LCSM |
| Brendon Stiles @BrendonStilesMD T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.co/Qw2G4o4Dli |
| Eric Bernicker MD FASCO @EricBernicker @BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for such a long time. Very exciting #LCSM |
| #LCSM Chat @lcsmchat I see you @CCuadra8! Thanks for joining us. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #T… |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first line yet. But promising first step that will lead to better treatments soon #LCSM |
| Brendon Stiles @BrendonStilesMD T2. And here are the results: #lcsm https://t.co/7zZWgEK5lz |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatmen… |
| Henning Willers, MD, FASTRO @HenningWillers RT @BrendonStilesMD: T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.… |
| Eric Bernicker MD FASCO @EricBernicker @CharuAggarwalMD Reflex panel tissue testing up front along with ctDNA. |
| #LCSM Chat @lcsmchat RT @EricBernicker: @BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for… |
| Brendon Stiles @BrendonStilesMD @EricBernicker I am so on the look out for a Wonka ticket! #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so till we see data in the 1L setting, we should use these in 2L #LCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first li… |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T2: this subset of cancers can also respond quite well to immunotherapy and those responses can be exceptionally durable. I’m not willing to trade that for the targeted agents just yet. So the first line setting for me is still immunotherapy-based. #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so t… |
| Brendon Stiles @BrendonStilesMD T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD [REDACTED USER] What is the national NGS model? #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat |
| Brendon Stiles @BrendonStilesMD T2. Great thread from @Jbauml about the trial. #lcsm https://t.co/oWOjlppjih |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: @BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for… |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first li… |
| @KimballKristen @StephenVLiu @BrendonStilesMD Hoping now, will be hopping w joy when it happens #lcsm | |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. And here are the results: #lcsm https://t.co/7zZWgEK5lz |
| Brendon Stiles @BrendonStilesMD T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From [REDACTED USER] https://t.co/lENIV32HJ0 |
| #LCSM Chat @lcsmchat I see you @ErikaHlavacek! Thanks for joining. #lcsm |
| Henning Willers, MD, FASTRO @HenningWillers RT @BrendonStilesMD: T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM |
| @KimballKristen @lgreco_ny @StephenVLiu @BrendonStilesMD T1 yes or will #lcsm | |
| KRASKickers @KRASKickers @EricBernicker @lcsmchat @BrendonStilesMD would you consider this a Wonka copper or silver ticket ? |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here. Happy to be able to join the #lcsm discussion. #PatientsFirst |
| Brendon Stiles @BrendonStilesMD T2. Important to remember that these are pretreated patients. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so t… |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD Hi Tim! #lcsm |
| Sue McCullough @SueMcCu30398663 I have at least updated my profile. #LCSM |
| Henning Willers, MD, FASTRO @HenningWillers @BrendonStilesMD @HemOncToday Unfortunately the response rates really come down. Combination drug therapies will be needed #lcsm |
| #LCSM Chat @lcsmchat @jillfeldman4 @CCuadra8 If someone “likes” a tweet, I can see it. #lcsm |
| KRASKickers @KRASKickers RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #T… |
| #LCSM Chat @lcsmchat Hi @JohnLPender! Hope you’re doing OK. #LCSM |
| Brendon Stiles @BrendonStilesMD @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from [REDACTED USER] https://t.co/lk6QYQgdNj |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy, @BrendonStilesMD! #lcsm |
| KRASKickers @KRASKickers [REDACTED USER] @BrendonStilesMD As more #biomarkers become actionable, it is crucial. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Great thread from @Jbauml about the trial. #lcsm https://t.co/oWOjlppjih |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbl… |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments, quite distinct from EGFR/ALK/ROS. I think 37% is pretty exciting! #LCSM |
| Brendon Stiles @BrendonStilesMD T3 coming soon! #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from [REDACTED USER] https://t.co/lk6QYQgdNj |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbl… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #hope #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM |
| #LCSM Chat @lcsmchat @SueMcCu30398663 Love the pic! #lcsm |
| Brendon Stiles @BrendonStilesMD T3. What is new in mesothelioma and small cell lung cancer? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD 2d that! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from [REDACTED USER] https://t.co/lk6QYQgdNj |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments,… |
| Jill Feldman @jillfeldman4 T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered un-targetable. #LCSM |
| Eric Bernicker MD FASCO @EricBernicker @JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could potentially benefit is immense. Many years of effort and study and prayer on that waterfall plot... #LCSM |
| Deepti Behl, M.D. @deeptibehl1 [REDACTED USER] Blood 🩸 based testing showing promise #lcsm |
| KRASKickers @KRASKickers RT @BrendonStilesMD: T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments,… |
| Brendon Stiles @BrendonStilesMD T3. Mesothelioma and small cell are too often left behind. Both terrible diseases. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered… |
 | Erika Hlavacek @ErikaHlavacek so true with unmet need! |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered… |
| Brendon Stiles @BrendonStilesMD T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From [REDACTED USER] https://t.co/ZqNPtLVmNv |
| #LCSM Chat @lcsmchat RT @deeptibehl1: [REDACTED USER] Blood 🩸 based testing showing promise #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Mesothelioma and small cell are too often left behind. Both terrible diseases. #lcsm |
| Henning Willers, MD, FASTRO @HenningWillers @BrendonStilesMD @HemOncToday [REDACTED USER] Naturally we are working on combining KRAS G12C inhibition with #radiotherapy #radonc #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From [REDACTED USER] https://t.co/ZqNPtLVmNv |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD @HemOncToday [REDACTED USER] Naturally we are working on combining KRAS G12C inhibition with #radiothera… |
| Sue McCullough @SueMcCu30398663 #LCSM Lillian,I think next time I need you socially distant showing me how to 'be apart of the discussions.' |
| Brendon Stiles @BrendonStilesMD @HenningWillers @HemOncToday [REDACTED USER] #lcsm https://t.co/KflK3kTovA |
 | Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @JFreemanDaily: @BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD [REDACTED USER] @HenningWillers @BrendonStilesMD @HemOncToday Unlike single oncogene driven tumors, KRAS MT tumors often have other co-occuring mutations and complex tumor microenviroment interplay may reduce sensitivity to TKIs #LCSM |
| Eric Bernicker MD FASCO @EricBernicker @BrendonStilesMD Significant benefit of immunotherapy in Meso and exciting clarification of molecular sub-classification in small cell that could really facilitate better trials #LCSM |
| Brendon Stiles @BrendonStilesMD T3. Still a long way to go for this terrible disease, but Nivolumab improved overall survival, specifically for the epithelioid subtype. #lcsm https://t.co/9Upt4PEf2F |
| Dave Bjork @bjork5 This is amazing! #research #liquidbiopsy #LCSM |
| #LCSM Chat @lcsmchat Hey @Tricia_Braun! Hope you’re doing well. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Still have to determine how best to handle first line treatment and to identify predictors of response. From @DrJNaidoo #lcsm https://t.co/8XdDcY2RPA |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: [REDACTED USER] @HenningWillers @BrendonStilesMD @HemOncToday Unlike single oncogene driven tumors, KRAS MT tumors ofte… |
| #LCSM Chat @lcsmchat RT @EricBernicker: @BrendonStilesMD Significant benefit of immunotherapy in Meso and exciting clarification of molecular sub-classification… |
| Dave Bjork @bjork5 This! 👇👇👇 #lcsm @kRasKickers |
| Sue McCullough @SueMcCu30398663 #LCSM the photo, not mine oneis my cat Tess. |
| Brendon Stiles @BrendonStilesMD T3. Several great talks on small cell lung cancer as well. #lcsm From [REDACTED USER] https://t.co/GXtY9ljAOX |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Awful #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung cancer. #lcsm https://t.co/se4kFIxJmE |
| Jill Feldman @jillfeldman4 T3 I thought the data on the high rates of pathologic germline mutations in #SCLC were very interesting! 67%! Interested in seeing more studies #LCSM |
 | Linnea Olson @1111linno T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some progress. #lcsm |
| Henning Willers, MD, FASTRO @HenningWillers RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung canc… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Several great talks on small cell lung cancer as well. #lcsm From [REDACTED USER] https://t.co/GXtY9ljAOX |
| Dave Bjork @bjork5 💯 #lcsm #PrecisionMedicine |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung canc… |
| Brendon Stiles @BrendonStilesMD T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co/4mR8Kuc8tt #lcsm |
| #LCSM Chat @lcsmchat RT @1111linno: T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some… |
| Anything's Natural Skincare @AnythngsNatural @_YSMaintain https://t.co/w2KsnWvWa2 Our whipped body butters are all natural, organic and cruelty free. Each is crafted for those with all skin types and caters to skin types that are dry, sensitive, Eczema and Psoriasis prone. https://t.co/i49OIk3p3T |
| Brendon Stiles @BrendonStilesMD T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co… |
| Linnea Olson @1111linno T3 But never enough ;) #lcsm |
| Eric Bernicker MD FASCO @EricBernicker @BrendonStilesMD @LaurenByersMD Agree this is very exciting and valuable work #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From [REDACTED USER] https://t.co/ZqNPtLVmNv |
| Dave Bjork @bjork5 @n8pennell This is so promising! 🙏🏽 #lcsm #kras #PrecisionMedicine |
| Brendon Stiles @BrendonStilesMD Where is @jillfeldman4? T4 coming next! #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies.… |
| Brendon Stiles @BrendonStilesMD T4. How can we make clinical trials better and more patient centric? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #LiquidBiopsy #lcsm |
| Dave Bjork @bjork5 Again, this! 👇 #LCSM #research |
| Brendon Stiles @BrendonStilesMD T4. Key to think about the patient perspective from the very beginning of trial design. #lcsm |
| Sara Whitlock @sjwhitlock T4. Early involvement!!!#LCSM |
| Jill Feldman @jillfeldman4 @BrendonStilesMD Haha, I stepped away for one minute to finish dinner! I'm delayed as well with these tweets for some reason |
| Linnea Olson @1111linno T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Key to think about the patient perspective from the very beginning of trial design. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Need to work hard to get past surgical therapy. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm https://t.co/mSghvVJZ8B |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Need to work hard to get past surgical therapy. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm… |
| @MomsOopsBaby RT @1111linno: T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some… | |
| Sara Whitlock @sjwhitlock T4. Jill has said it best. What is important to the researcher not always same to the patient. #LCSM |
| Jill Feldman @jillfeldman4 T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo |
 | Erik C. Thauvin @ethauvin World Cancer Day #IAmAndIWill https://t.co/40nZBCbBUr https://t.co/8T9E6WebAf |
| Brendon Stiles @BrendonStilesMD T4. We should be able to expand eligibility. #lcsm https://t.co/HhmFahchcj |
| Sara Whitlock @sjwhitlock T4. Expand inclusion criteria #LCSM |
| Dave Bjork @bjork5 @HemOncToday @IASLC @sloan_kettering @MMarmarelis @Penn Impressive! #lcsm @BrendonStilesMD @CharuAggarwalMD |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T4. Jill has said it best. What is important to the researcher not always same to the patient. #LCSM |
| Henning Willers, MD, FASTRO @HenningWillers RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered aroun… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. We should be able to expand eligibility. #lcsm https://t.co/HhmFahchcj |
| Jill Feldman @jillfeldman4 T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but only patients and caregivers are impacted by every decision made from the beginning and throughout the entire process. Yet, not always included! #LCSM https://t.co/nwPAF1c7u1 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T4. Expand inclusion criteria #LCSM |
| Sue McCullough @SueMcCu30398663 #LCSM Advocates as apart of the trial design! |
| Brendon Stiles @BrendonStilesMD T4. @iaslc has done a good job taking lead on addressing this. #lcsm https://t.co/uuzTDdjN33 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung canc… |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm |
| #LCSM Chat @lcsmchat RT @SueMcCu30398663: #LCSM Advocates as apart of the trial design! |
| Linnea Olson @1111linno T4 I had to pay out of pocket costs today for drug to combat side effects of clinical trial drug. Why would sponsor not pick up cost? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. @iaslc has done a good job taking lead on addressing this. #lcsm https://t.co/uuzTDdjN33 |
 | Tim Broyle, MD @BroyleTim RT @jillfeldman4: T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but on… |
 | Know Your Lemons 🍋🍋 @knowyourlemons Session 2 of World Cancer Day Global Webinar for our Educators is DONE. Thank you to all of our educators that make our job so rewarding. 💛💛 #knowyourlemons #breastcancer #breastcancerawareness https://t.co/emG2ZmoWJw |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Go @1111linno! #lcsm |
| Linnea Olson @1111linno T4 Talk to patients but talk to the RIGHT patients. Those who have participated in trials. And or been excluded from participation. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Good to discuss and prioritize endpoints important to patients – survival, recurrence, quality of life. It is what is important to them, not so much us. #lcsm |
| mimiprovenzano @MimiProvenzano RT @TimAllenMDJD: Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm ht… |
| Peggy Dennis @peggyddennis T4 - Expand to driver mutations across different cancer types. I.e. breast/ lung/gastric. Lots of data #lcsm |
| Dave Bjork @bjork5 @1111linno T4 great timing for your entrance! #lcsm #patients 💯💯💯💯 |
| Brendon Stiles @BrendonStilesMD T4. Also important to acknowledge the role patients play in every advance we make. #lcsm From [REDACTED USER] https://t.co/j6eDKPc4sV |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co… |
| Jill Feldman @jillfeldman4 T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and doesn't adress the fact that people in under resourced communities don't participate because they aren't aware and/or not asked! #LCSM https://t.co/rRfazYT5yk |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt |
| Sara Whitlock @sjwhitlock T4. Also improve PROs. #LCSM |
| Brendon Stiles @BrendonStilesMD T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but on… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @SueMcCu30398663: #LCSM Advocates as apart of the trial design! |
| Brendon Stiles @BrendonStilesMD T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https://t.co/FETEC3m3zi |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies.… |
| #LCSM Chat @lcsmchat RT @1111linno: T4 Talk to patients but talk to the RIGHT patients. Those who have participated in trials. And or been excluded from partici… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Good to discuss and prioritize endpoints important to patients – survival, recurrence, quality of life. It is wh… |
| Dave Bjork @bjork5 @jillfeldman4 Volunteers are VIPs #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Also important to acknowledge the role patients play in every advance we make. #lcsm From [REDACTED USER] https://… |
| Brendon Stiles @BrendonStilesMD [REDACTED USER] Definitely deserving of an in depth discussion. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD We MUST continue to address! #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and… |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T4. Also improve PROs. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD @JFreemanDaily Terrific, Janet! |
 | Conquering CHD - Tennesee @conqueringchdtn Don’t forget to wear red tomorrow 2/5/21! Post your pictures and tag us in them. Can’t wait to see all the red. #conqueringchd #conqueringchdtn #hope #heartmonth https://t.co/m9ugZzmPr8 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https:… |
| #LCSM Chat @lcsmchat RT @bjork5: @jillfeldman4 Volunteers are VIPs #lcsm |
| Linnea Olson @1111linno T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, physical. #lcsm |
| Brendon Stiles @BrendonStilesMD This.... #lcsm |
| #LCSM Chat @lcsmchat RT @1111linno: T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, p… |
 | Dr. Amy C. Moore @acmoorephd Sorry I'm late to the party #LCSM |
| Jill Feldman @jillfeldman4 T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be written to include those requirements, which means they will be in the protocol & so on. #LCSM |
| Matthew Smeltzer @MattSmeltzer RT @TimAllenMDJD: We MUST continue to address! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #QualityOfLife is too often overlooked or minimized. #lcsm |
| @KimballKristen @jillfeldman4 thank you for caregiver inclusion #lcsm | |
| Dr. Amy C. Moore @acmoorephd RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered aroun… |
| Brendon Stiles @BrendonStilesMD Homestretch....T5 coming up. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be… |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: #QualityOfLife is too often overlooked or minimized. #lcsm |
| KRASKickers @KRASKickers RT @BrendonStilesMD: This.... #lcsm https://t.co/juca7KhUC2 |
| Janet Freeman-Daily @JFreemanDaily T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate disparities in age, income, socioeconomic factors. #LCSM https://t.co/k6w69irIwB |
| Linnea Olson @1111linno T4 Change the language. Scratch noncompliant. And volunteer. I am not a fucking volunteer. Cancer chose me and I was desperate. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: We MUST continue to address! #lcsm https://t.co/yZC02tDxLp |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #PatientsFirst #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @1111linno: T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, p… |
| KRASKickers @KRASKickers RT @BrendonStilesMD: T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https:… |
| Brendon Stiles @BrendonStilesMD T5. How can we improve access to and affordability of lung cancer care? #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @JFreemanDaily: T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate dispa… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: This.... #lcsm https://t.co/juca7KhUC2 |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be… |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate dispa… |
| Matthew Smeltzer @MattSmeltzer Agree! Including selection of endpoints |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: #QualityOfLife is too often overlooked or minimized. #lcsm https://t.co/uEfafwxSQ5 |
| Brendon Stiles @BrendonStilesMD T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that they are available to all patients. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI |
| Dr. Amy C. Moore @acmoorephd As @jillfeldman4 said in her #WCLC20 talk, let's not forget the 80% of patients under water #lcsm @IASLC |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. How can we improve access to and affordability of lung cancer care? #lcsm |
| Inspire @InspireIsHealth RT @BrendonStilesMD: T5. How can we improve access to and affordability of lung cancer care? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that the… |
| #LCSM Chat @lcsmchat RT @acmoorephd: As @jillfeldman4 said in her #WCLC20 talk, let's not forget the 80% of patients under water #lcsm @IASLC |
| Brendon Stiles @BrendonStilesMD T5. Literacy is one key element. #lcsm From @jillfeldman4 https://t.co/fkwt26LjXJ |
| Sara Whitlock @sjwhitlock T5. Must decentralize. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD @JFreemanDaily, #lcsm superstar! |
| Linnea Olson @1111linno T5 Bring it to the patient instead of expecting the patient to come to it. Telehealth but also informed local oncologists. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that matters to the PATIENT, tailored to the disease and type of treatment. #LCSM |
| Brendon Stiles @BrendonStilesMD T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20 https://t.co/qdBTUATm4R |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T5. Must decentralize. #LCSM |
| #LCSM Chat @lcsmchat RT @1111linno: T5 Bring it to the patient instead of expecting the patient to come to it. Telehealth but also informed local oncologists.… |
| Jill Feldman @jillfeldman4 T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and successful for them. As 'Who is NOT at the table' starting at R & D #LCSM |
| Brendon Stiles @BrendonStilesMD T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #lcsm https://t.co/rFvclJ7SSn |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: #PatientsFirst #lcsm https://t.co/AorQl0isa8 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20… |
| Dave Bjork @bjork5 “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMachos @CaptainClinical #patients #clinicaltrials |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and succ… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that the… |
| Brendon Stiles @BrendonStilesMD T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm |
| Jill Feldman @jillfeldman4 T4 The most important 'End Point' in a trial is the patient! #LCSM |
| KRASKickers @KRASKickers RT @BrendonStilesMD: T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Literacy is one key element. #lcsm From @jillfeldman4 https://t.co/fkwt26LjXJ |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm |
| KRASKickers @KRASKickers RT @bjork5: @n8pennell This is so promising! 🙏🏽 #lcsm #kras #PrecisionMedicine |
| Brendon Stiles @BrendonStilesMD T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 The most important 'End Point' in a trial is the patient! #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T5. Hard to imagine everyone having access to these exciting therapies unless something is done about drug costs. Some $20k/month now and goes up annually #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: @JFreemanDaily, #lcsm superstar! https://t.co/gmpjxD5Nms |
| KRASKickers @KRASKickers RT @bjork5: 💯 #lcsm #PrecisionMedicine https://t.co/B25XhZRQbO |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Rural and inner city patients. Racial minorities. LGBTQ. #lcsm |
| Eric Bernicker MD FASCO @EricBernicker @BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds these days center on dealing with patients with no insurance or who are out of network or who have little family support #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm |
| Jill Feldman @jillfeldman4 T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silence only perpetuates injustice. EVERYONE needs to do their part #LCSM |
 | virginia litle @vlitlemd T5 access to screening for all (underserved) takes educating those who fear stigma of cancer/screening #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Rural and inner city patients. Racial minorities. LGBTQ. #lcsm |
| Linnea Olson @1111linno T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disparity. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silen… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #… |
| Jill Feldman @jillfeldman4 T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities and other groups also face disparities and barriers and need to be represented. #LCSM |
| Brendon Stiles @BrendonStilesMD T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems, insurance, and industry to seriously address. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @bjork5: “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMac… |
| Jamie Holloway, PhD @jamienholloway @jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the big protocols. It’s the sponsors. So glad they are listening more now, too. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #equity #NoStigma #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T4 The most important 'End Point' in a trial is the patient! #LCSM |
| Brendon Stiles @BrendonStilesMD T5. As always, @fumikochino taking the lead on discussions of financial toxicity #lcsm: https://t.co/t1TGC42z7z |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: T5. Hard to imagine everyone having access to these exciting therapies unless something is done about drug costs. Some $20k/… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Rural and inner city patients. Racial minorities. LGBTQ. #lcsm https://t.co/ovffKGDzSV |
| Linnea Olson @1111linno T5 Lack of information/access is an issue but so is lack of resources. And fear. We must help each other out. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #… |
| Brendon Stiles @BrendonStilesMD T5. And from @DevikaDasMD #lcsm https://t.co/ounoFtDJpr |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silen… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @bjork5: “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMac… |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T5. This! I’d like to see a fraction of $ spent on drugs applied to getting every single eligible patient tested worldwide #LCSM |
| #LCSM Chat @lcsmchat RT @jamienholloway: @jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the… |
| Jill Feldman @jillfeldman4 T5 Collaborate with community hospitals and minority physicians – physicians are a trusted voice in the community and people trust people who are more like them. This should be written into funding! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Word #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jamienholloway: @jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. As always, @fumikochino taking the lead on discussions of financial toxicity #lcsm: https://t.co/t1TGC42z7z |
| #LCSM Chat @lcsmchat RT @1111linno: T5 Lack of information/access is an issue but so is lack of resources. And fear. We must help each other out. #lcsm |
| Brendon Stiles @BrendonStilesMD Undoubtedly a major challenge. I am going to jump all over it at @MontefioreNYC and @EinsteinMed #lcsm. This has to change. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. And from @DevikaDasMD #lcsm https://t.co/ounoFtDJpr |
| #LCSM Chat @lcsmchat RT @n8pennell: T5. This! I’d like to see a fraction of $ spent on drugs applied to getting every single eligible patient tested worldwide #… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Walk the talk. #lcsm |
| @ Check out my talk on 'Skin Stories' with Dr. Trevor Cates. Here we discuss nutrition and herbs that to reduce eczema and dermatitis. https://t.co/FpFMa3pc9T | |
| Brendon Stiles @BrendonStilesMD T5. #COVID19 has certainly also affected access to care. #lcsm From [REDACTED USER]: https://t.co/Kkcq8PUUm9 |
| @ RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From [REDACTED USER]: https://t.co/Kkcq8PUUm9 | |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems,… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Undoubtedly a major challenge. I am going to jump all over it at @MontefioreNYC and @EinsteinMed #lcsm. This has to c… |
| Dave Bjork @bjork5 Big issue. I don’t have the answer, but every lung cancer patient deserves access to genomic testing and latests treatments, academic or community setting. @OneOncology @FoundationATCG #lcsm #PrecisionMedicine |
 | emily.elswick @ElswickEmily RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that the… |
| @ Check out my talk on 'Skin Stories' with Dr. Trevor Cates. Here we discuss nutrition and herbs that help to reduce eczema and dermatitis. https://t.co/FpFMa3pc9T | |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From [REDACTED USER]: https://t.co/Kkcq8PUUm9 |
| Janet Freeman-Daily @JFreemanDaily T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: patients, disadvantaged community members, providers, researchers, payers, regulatory agencies, pharmacy benefit managers, pharma, biotech, advocates, nonprofits ... #LCSM |
| Sara Whitlock @sjwhitlock I talk to a lot of newly diagnosed people. Shocked at how many have not had bio marker testing. #lcsm |
| Brendon Stiles @BrendonStilesMD Almost time to wind the chat down. This has been a great discussion. It is always therapeutic for me to see each of you here and to surround myself in this community. #lcsm |
| Eric Bernicker MD FASCO @EricBernicker @sjwhitlock And are not aware that they are missing out on key information #LCSM |
| Brendon Stiles @BrendonStilesMD This is shocking indeed. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @n8pennell I'd love to see the money that's currently spent on creating new "get biomarker testing!" websites applied to increasing provider education on the ground. #LCSM |
| Jill Feldman @jillfeldman4 T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of people with #lungcancer because of disparities Everyone below the water in this graph! #LCSM https://t.co/B3nYNnsnUq |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @n8pennell I'd love to see the money that's currently spent on creating new "get biomarker testing!" websites applied to… |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of peopl… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of peopl… |
| Sue McCullough @SueMcCu30398663 #LCSM Money collected in smoker's tax, spent on research and treatment or get the manufacturers to pay. |
| Brendon Stiles @BrendonStilesMD Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2ZpZT |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2… |
| Brendon Stiles @BrendonStilesMD Please share your closing thoughts! #lcsm |
| Sue McCullough @SueMcCu30398663 #LCSM Oops should have put T5 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2… |
| Jill Feldman @jillfeldman4 T5 JUSTICE #LCSM #healthequity https://t.co/MBj4opWCTD |
| Linnea Olson @1111linno T5 We need to recognize that this group is like a Salon. We are not representative. Our very presence here speaks of privilege. #lcsm |
| Dr. Amy C. Moore @acmoorephd @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network of Centers of Excellence #lcsm |
| #LCSM Chat @lcsmchat RT @1111linno: T5 We need to recognize that this group is like a Salon. We are not representative. Our very presence here speaks of privile… |
| #LCSM Chat @lcsmchat RT @acmoorephd: @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network… |
| Linnea Olson @1111linno T5 And yet we must represent. In order to do so, we have to ask lots of questions. Be observant. And always humble. #lcsm |
| Sara Whitlock @sjwhitlock I think about this ALL the time. #LCSM |
| Brendon Stiles @BrendonStilesMD I would have loved to have spent time with all of you in Singapore! #lcsm #wclc20 Virtual conferences are more accessible and allow broader particpation, but I miss the face to face. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Walk the talk. #lcsm https://t.co/6FXwLAgEZd |
| #LCSM Chat @lcsmchat Thank you @BrendonStilesMD for moderating tonight. We appreciate you! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From [REDACTED USER]: https://t.co/Kkcq8PUUm9 |
| #LCSM Chat @lcsmchat RT @1111linno: T5 And yet we must represent. In order to do so, we have to ask lots of questions. Be observant. And always humble. #lcsm |
| Brendon Stiles @BrendonStilesMD Hoping #WCLC21 or #WCLC22 is in person. If so, find me. Drinks on me! Would love to talk to each of you. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @sjwhitlock: I talk to a lot of newly diagnosed people. Shocked at how many have not had bio marker testing. #lcsm https://t.co/Jk7BrsUy… |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: @sjwhitlock And are not aware that they are missing out on key information #LCSM |
| Brendon Stiles @BrendonStilesMD RT @acmoorephd: @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network… |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of peopl… |
| @CroixDenise @BrendonStilesMD Thank you for a very informative discussion! #lcsm | |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Yes, many thanks @BrendonStilesMD for moderating this excellent #lcsm twitterchat. It was a privilege to participate. |
 | benjamin wu @benjaminwumd RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co… |
| Jill Feldman @jillfeldman4 T5 Let's all take a pledge & commit to self-reflection, to acknowledging disparities exist, funding minority scientists, embedding a ‘health equity’ lens into all initiatives and programs, advocating for antiracism and to prioritize people over profits. #LCSM |
 | Narjust Florez, MD, FASCO @NarjustFlorezMD RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S… |
| Janet Freeman-Daily @JFreemanDaily RT @1111linno: T5 We need to recognize that this group is like a Salon. We are not representative. Our very presence here speaks of privile… |
| Dr. Amy C. Moore @acmoorephd Also, how do we expand early detection? Not just LDCT screening but how do we effectively address incidental findings too? @GO2Foundation is also working to address this opportunity in our Centers of Excellence. |
| Brendon Stiles @BrendonStilesMD I am even buying for #RadOnc! I even miss them! Desperately! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network… |
| Janet Freeman-Daily @JFreemanDaily RT @1111linno: T5 And yet we must represent. In order to do so, we have to ask lots of questions. Be observant. And always humble. #lcsm |
| Matthew Smeltzer @MattSmeltzer Good to hear from everyone, so much recent progress, yet so much more needed! #LCSM @lcsmchat |
| Brendon Stiles @BrendonStilesMD @acmoorephd @GO2Foundation Let's talk about incidental nodules! I have big plans and need your help. #lcsm |
| Linnea Olson @1111linno @TimAllenMDJD Yes. Big YES. |
| Sue McCullough @SueMcCu30398663 #LCSM Just a big thank you for all your passion.🫁 |
| Dr. Amy C. Moore @acmoorephd RT @JFreemanDaily: T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate dispa… |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD #WCLC21 is virtual but looking forward to that drink at #WCLC22! |
 | Gia Sonata @RedGia @BrendonStilesMD T5 - Many cancer ctrs have finance offices to find programs/charities to assist w/medical bills but often they just send the documents, which require add'l docs & we are OVERWHELMED! Would be nice to augment these offices w/volunteers/interns to help pts complete docs. #LCSM |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: @acmoorephd @GO2Foundation Let's talk about incidental nodules! I have big plans and need your help. #lcsm |
| Henning Willers, MD, FASTRO @HenningWillers @BrendonStilesMD https://t.co/hZ8qII7j5E |
| Jill Feldman @jillfeldman4 T5 Thanks @BrendonStilesMD for great moderating as always...and as always I couldn't keep up so can't wait to go back see the discussion #LCSM |
| Narjust Florez, MD, FASCO @NarjustFlorezMD @lcsmchat @BrendonStilesMD Oh no... I missed it 😔 #LCSM |
| Brendon Stiles @BrendonStilesMD @StephenVLiu I might just go to Denver and see what happens.... #lcsm |
| @KimballKristen Thank you all, again. It is a privilege to participate in these illuminating discussions. #LCSM | |
| #LCSM Chat @lcsmchat RT @RedGia: @BrendonStilesMD T5 - Many cancer ctrs have finance offices to find programs/charities to assist w/medical bills but often the… |
| mimiprovenzano @MimiProvenzano @jillfeldman4 @BrendonStilesMD Same! #lcsm |
| Dave Bjork @bjork5 @lcsmchat @BrendonStilesMD 💯 thank you @BrendonStilesMD ...and others on the frontline of care for our community @CharuAggarwalMD @HenningWillers @n8pennell @DavidCookeMD @StephenVLiu @TimAllenMDJD @NarjustDumaMD ... so many others. #lcsm |
| Brendon Stiles @BrendonStilesMD Cheers my friend! Great podcast with @bjork5! #LCSM |
| Jill Feldman @jillfeldman4 T5 So grateful for this community. Hope to see you all IRL sooner than later. Be well, stay safe and stay sane #LCSM |
| Janet Freeman-Daily @JFreemanDaily Thank you @BrendonStilesMD for the great topics and (as usual) well-prepared tweets. Great overview of important #WCLC20 presentations! May progress in #Lungcancer awareness, testing, treatments, and equity continue. #LCSM |
| Narjust Florez, MD, FASCO @NarjustFlorezMD @BrendonStilesMD 100% need to see you all! Don't remember how [REDACTED USER] and [REDACTED USER] look. |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Thank you @BrendonStilesMD for the great topics and (as usual) well-prepared tweets. Great overview of important #WCLC20… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: I would have loved to have spent time with all of you in Singapore! #lcsm #wclc20 Virtual conferences are more acces… |
 | Christine Garcia, MD, MPH @christinemphmd @BrendonStilesMD Thanks @BrendonStilesMD! Certainly enlightening! #lcsm |
| Brendon Stiles @BrendonStilesMD @MimiProvenzano @jillfeldman4 Miss you @MimiProvenzano. Hope all is well! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Hoping #WCLC21 or #WCLC22 is in person. If so, find me. Drinks on me! Would love to talk to each of you. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @bjork5: @lcsmchat @BrendonStilesMD 💯 thank you @BrendonStilesMD ...and others on the frontline of care for our community @CharuAggarwal… |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: Thank you @BrendonStilesMD for the great topics and (as usual) well-prepared tweets. Great overview of important #WCLC20… |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T5 Thanks @BrendonStilesMD for great moderating as always...and as always I couldn't keep up so can't wait to go back see… |
| mimiprovenzano @MimiProvenzano @BrendonStilesMD @jillfeldman4 Miss you, too! Congratulations on Montefiore! 🎉🎉🎉 #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T5 So grateful for this community. Hope to see you all IRL sooner than later. Be well, stay safe and stay sane #LCSM |
| Jill Feldman @jillfeldman4 We need to be conscious of this as the field of genomics rapidly progresses & need for more therapies continues to be an urgent need #LCSM |
| @aepriceny @BrendonStilesMD Thanks for all you do! Will be seeing you in March! We’re a year along here! #lcsm | |
| Dr. Amy C. Moore @acmoorephd @BrendonStilesMD @GO2Foundation Yes, let's talk :) #lcsm |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD https://t.co/C7pujGBJK3 |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Just read 2 excellent viewpoints in @JAMAOnc and I could hear the voices of @n8pennell and @JackWestMD as I was reading each word. Well done! [REDACTED USER] #ADAURA #LCSM https://t.co/RNJ1p4rnFB |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: We need to be conscious of this as the field of genomics rapidly progresses & need for more therapies continues to be an… |
 | Beth Kulow @ehgkulow RT @lgreco_ny: Please share like your life depends on it. LIVES DO DEPEND ON IT. Churchill: Why won't New York vaccinate the vulnerable? #l… |
| Dave Bjork @bjork5 @LaurenMachos @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @CaptainClinical Thank you for leadership too Lauren 🙌 #LCSM #wclc2020 |
 | Andrew Beardsley @Ladebuck @n8pennell Does “lead to better treatments soon” mean combo therapy? Or just optimism that probably Kevan Shokat will think of something else clever soon? If the former, what other targeted therapy combo could be a precedent for this claim? |
| Jill Feldman @jillfeldman4 Very important to have real world data complement existing research & clinical data. And with new treatments there needs to be new measurements for QOL. PROs don't represent the real world patient. I have some thoughts...#LCSM |
 | Naveen | नवीन | नVन 🌸 @naveenlaloshrma [REDACTED USER] [REDACTED USER] Sad news |
| Jill Feldman @jillfeldman4 @KimballKristen Always! I was a caregiver before a patient and have always said in so many ways it's much harder to be the caregiver! Plus, caregivers play a critical role in patient participation in trials, among everything else ❤️ #LCSM |
| Jill Feldman @jillfeldman4 RT @acmoorephd: As @jillfeldman4 said in her #WCLC20 talk, let's not forget the 80% of patients under water #lcsm @IASLC https://t.co/JUggg… |
 | Lauren Meehan Machos, MPH @LaurenMachos @JFreemanDaily @n8pennell Would love to talk about what more we could do to meet the provider education needs- it’s a Priorty focus and agree we need more education- clinicians, payers etc. |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell @CharuAggarwalMD @JAMAOnc @JackWestMD [REDACTED USER] Thanks Charu! |
| Jill Feldman @jillfeldman4 @BrendonStilesMD Yes, this is so important. But it has to be tailored to the community because those of black and African descent aren't a monolith. So many other factors and unique needs depending on the community #LCSM |
| Jill Feldman @jillfeldman4 @bjork5 @CraigLipset @joedustin @stales @Medidata @DaveFuehrer @ctraz @LaurenMachos @CaptainClinical I feel strongly about this! |
 | Drew Moghanaki @DrewMoghanaki Free and open to the public. RSVP by Feb 22nd. #lcsm https://t.co/rpXPYjow97 https://t.co/MfZGfSxYkW |
#LCSM content from Twitter.